key: cord-0986809-e1s0jg5e
authors: Lu, Ying-feng; Pan, Li-ya; Zhang, Wen-Wu; Cheng, Fang; Hu, Sha-Sha; Zhang, Xue; Jiang, Hai-yin
title: A meta-analysis of the incidence of venous thromboembolic events and impact of anticoagulation on mortality in patients with COVID-19
date: 2020-08-13
journal: International journal of infectious diseases : IJID : official publication of the International Society for Infectious Diseases
DOI: 10.1016/j.ijid.2020.08.023
sha: ddee0a9e2701b4418cca18d03ce86909f9e74f2a
doc_id: 986809
cord_uid: e1s0jg5e

Abstract Background The incidence of venous thromboembolic events (VTE) in patients with COVID-19 is generally high but varies markedly. However, the relationship between anticoagulation and mortality in patients with COVID-19 is still unclear. Methods We performed a systematic review and meta-analysis to determine the incidence of VTE and evaluate the role of anticoagulation in patients with COVID-19. Random effects models were used to determine overall pooled estimates and 95% confidence intervals (CIs). Results After a database search, 25 observational studies (20 on VTE incidence and 5 on the relationship between anticoagulation and mortality) were included. The pooled incidence rates of VTE, pulmonary embolism (PE), and deep vein thrombosis (DVT) in hospitalised COVID-19 patients were 21% (95% CI 15–27%), 15% (95% CI 10–20%), and 27% (95% CI 19–36%), respectively. A meta-analysis of five studies found that anticoagulation was not associated with an increased risk of mortality in hospitalised COVID-19 patients (RR = 0.86, 95% CI, 0.69–1.09, P = 0.218; I2 = 47.4%). Conclusions In conclusion, the incidence of VTE among hospitalised COVID-19 patients was high. Clinical trials are urgently needed to evaluate the roles of prophylactic and therapeutic anticoagulation in COVID-19.

participated in the design, acquisition, analysis and interpretation of data. All authors read and approved the final manuscript.

Since the outbreak of COVID-19 in December 2019, more than 6 million confirmed cases and 392,000 deaths have been reported worldwide as of June 1, 2020(1). Aside from the lungs, this disease may also cause severe injury to the heart(2), kidneys (3) , and liver(4) that can lead to death.

Emerging data suggest that severe acute respiratory syndrome coronavirus 2 (SARS-CoV-2) also targets the haematological system (5) . Venous thromboembolic events (VTE) were reported in a case series of COVID-19 patients (6) (7) (8) . In a very recent study (9) , autopsies performed on 12 consecutive COVID-19-positive patients revealed that pulmonary embolism (PE) was the direct cause of death in 4 patients. These observations have led to concerns that COVID-19 is associated with a risk of VTE.

Increasingly, studies (10) (11) (12) (13) (14) (15) (16) (17) (18) (19) (20) (21) (22) (23) (24) (25) (26) (27) (28) (29) have evaluated the incidence of VTE in COVID-19 patients, which tended to be higher among those in the intensive care unit (ICU).

However, the results have been very inconsistent. COVID-19 has been observed to be associated with elevated D-dimer levels and coagulopathy in patients, which increases the risk of death. This suggests that COVID-19 patients without medical 

To ensure that the work was of high quality, we followed the Preferred Reporting Items of Systematic Reviews and Meta-analysis (PRISMA) guidelines (Table S1 ). All steps were performed independently by two investigators with different specialties. Any disagreements were resolved by discussion between the two reviewers, or by a third reviewer.

The PubMed, EMBASE, and Cochrane Library databases were searched to identify all relevant articles published between Jan 1, 2020 and June 4, 2020. The World Health Organization (WHO) database and medRxiv.org were also searched for potentially relevant publications, including accepted articles yet to be published. The following keywords, and combinations thereof, were searched for: ("Corona Virus Disease-2019" OR "2019 novel coronavirus" OR "SARS-CoV-2" OR "COVID-19" OR "2019-nCoV") AND ("VTE" OR "PE" OR "DVT" OR "thromboembolism" OR "venous thrombosis" OR "pulmonary embolism" OR "deep venous thrombosis" OR "thrombotic" OR "anticoagulants" OR "factor Xa inhibitors" OR "heparinoids" OR "dabigatran" OR "rivaroxaban" OR "edoxaban" OR "apixaban" OR "heparin"). Reference lists of relevant articles were searched manually.

We included observational studies that reported the incidence of VTE in hospitalised patients with confirmed COVID-19. Studies not reporting clinical characteristics or clinical experience were excluded, as were case reports.

For studies that evaluated the effects of anticoagulation on mortality in patients with COVID-19, the following inclusion criteria were applied: (1) case-control or cohort study; (2) no subjects in the reference group receiving anticoagulants; (3) odds ratios (ORs), relative risks (RRs), or hazard ratios (HRs) of subsequent mortality reported; (4) inclusion of adequate data to allow risk estimation; and (5) written in English.

For studies that evaluated the rate of VTE in patients with COVID-19, the following information was extracted using a standardised data collection method: author, study origin, design, period, site, baseline characteristics, and number of COVID-19 cases and For studies that investigated the impact of anticoagulation on mortality, the following information was extracted using a standardised data collection method: author, study origin, design, period and site, baseline characteristics, number of cases receiving and not receiving anticoagulants, measurement of anticoagulation, and statistical adjustments. The methodological quality was assessed using the Newcastle-Ottawa Scale (NOS) (35) , which has eight criteria and yields scores ranging from 0 (high risk of bias) to 9 (low risk of bias). Studies with scores ≥ 7 were regarded as high quality.

J o u r n a l P r e -p r o o f the Freeman-Tukey double arcsine transformation applied. The data on mortality risk were pooled using a random effects model with the generic inverse variance method, as described by DerSimonian and Laird (36) . We used the I² statistic to assess statistical heterogeneity; an I 2 value > 50% was considered to indicate significant heterogeneity (37, 38) . Owing to the anticipated heterogeneity of the included studies, we used a random-effects model to estimate effect sizes, which would provide more conservative estimates of the 95% CIs. The statistical analyses were performed using Stata software (ver. 12.0; Stata Corp., College Station, TX, USA).

The electronic database and manual searches of the reference lists of relevant articles yielded 841 unique articles, and 212 duplicates. In total, 551 articles were excluded after reading the title and abstract. The full text of the remaining 78 articles was assessed in terms of suitability for the meta-analysis. Ultimately, our meta-analysis included 25 studies: 20 on DVT incidence and 5 on anticoagulation in COVID-19 patients. Fig. 1 summarises the number of articles by reason for exclusion at each stage of the eligibility assessment. Table 1 summarizes the characteristics of the included studies reporting the rate of VTE.

Fifteen studies were performed in Europe, two in USA and three in Chinese. The number of COVID-19 patients ranged from 26 to 400. Ten, four and six studies assessed the rate of VTE in patients only in the ICU, in both the ICU and general wards, and only in general wards, respectively. The mean age of the subjects ranged from 57 to 68 years and the proportion of males ranged from 52% to 81%. Table S2 presents the quality assessment results.

Eleven studies (10, 11, 13, 15-17, 20-22, 26, 27) reported the overall incidence of VTE (ICU and general wards), which ranged from 4% to 42%. VTE occurred in 255 of 1,808 hospitalised patients. The meta-analysis revealed a pooled incidence rate of VTE of 21% (95% CI 15-27%, I 2 = 94.8%; Fig.2A ) among all hospitalised patients. Eight (10, 13, 15, 16, (20) (21) (22) 27 ) studies reported the incidence of VTE in the ICU setting. VTE Twelve studies (11, 12, 16-20, 22, 24, 26, 27) reported the overall incidence of PE, which varied from 2% to 35%. PE occurred in 238 out of 1,793 hospitalised patients. The meta-analysis revealed a pooled incidence rate of PE of 15% (95% CI 10% -20%, I 2 = 93.5%; Fig.2C ) among all hospitalised patients. Eight studies (12, 16, 18, 20-22, 24, 27) reported the incidence of PE in the ICU setting. PE occurred in 148 of 690 ICU patients. A meta-analysis of the proportions revealed a pooled incidence of PE of 20% (95% CI 9-31%, I 2 = 49.6%; Fig.2D ) among ICU patients.

Nine studies (14, 16-18, 23-26, 28, 29) reported the overall incidence of DVT, which varied from 2% to 85%. DVT occurred in 212 out of 1,243 hospitalised patients.

The meta-analysis revealed a pooled incidence rate of DVT of 27% (95% CI 19% -36%, I 2 = 98.3%; Fig.2E ) among all hospitalised patients. Seven studies (16, 18, (23) (24) (25) 28 ) reported the incidence of DVT in the ICU setting. DVT occurred in 99 out of 579 ICU patients. Meta-analysis revealed a pooled incidence of DVT of 33% (95% CI 19% -47%, I 2 = 98.8%; Fig.2F ) among ICU patients. Table 2 summarises the characteristics of the included studies reporting the impact of anticoagulation on mortality. Four studies were performed in Europe and the USA; only one was conducted in China. Although two studies evaluated the impact of pre-admission antithrombotic therapy, patients who discontinued antithrombotic drugs during hospitalisation were excluded. The number of COVID-19 patients ranged from 192 to 3,100. The mean age of the subjects ranged from 56 to 67 years, and the proportion of males ranged from 55% to 60%. Table S3 presents the quality assessment results.

This analysis included five studies(30-34), including 2,886 and 5,647 COVID-19 cases receiving and not receiving anticoagulants, respectively. Overall, the risk of mortality was similar between the anticoagulant-exposed and non-exposed COVID-19 patients (RR = 0.86, 95% CI, 0.69-1.09, P = 0.218; I 2 = 47.4%; Fig.2 ). Limiting the analysis to the studies providing adjusted data, there was no significant decrease in mortality risk in patients receiving anticoagulant therapy (RR = 0.84, 95% CI, 0.63-1.13, P = 0.243; I 2 = 57.6%). Excluding two studies that specified pre-admission antithrombotic therapy, the meta-analysis of the remaining three studies also found that anticoagulation was not associated with a lower risk of mortality (RR = 0.79, 95% CI, 0.48-1.31, P = 0.361; I 2 = 55.8%).

To our knowledge, this is the first systematic review and meta-analysis of the incidence of VTE and effects of anticoagulation on mortality in patients with COVID-19. We found that the overall rates of VTE, PE, and DVT were high (pooled incidence rates of 21%, 15%, and 27%, respectively). These rates were higher among patients admitted to the ICU, and antithrombotic therapy was not associated with a lower mortality risk.

Although the relationship between SARS-CoV-2 and VTE was reported soon after the COVID-19 outbreak (39, 40) , the underlying mechanism requires further exploration.

The first possible mechanism is cytokine storm caused by viral infection. Several studies have reported significantly higher plasma cytokine concentrations in COVID-19 patients than in healthy adults (41) (42) (43) . Furthermore, an elevated IL-6 level was J o u r n a l P r e -p r o o f associated with more severe COVID-19 infection (41, 44) . Inflammatory cytokines, such as TNF-α and IL-6, strongly induce the expression of tissue factors on endothelial cell surfaces and leucocytes, particularly monocytes (45, 46) . Tissue factors are the primary initiator of the blood coagulation cascade and strongly contribute to the hypercoagulable state in COVID-19 infection. Inflammatory cytokines can also trigger the release of ultra-large von Willebrand factor multimers from the endothelium(47), causing thrombotic microangiopathy; this has been confirmed at autopsy in patients who died from COVID-19 (48) . Finally, the concentrations of vascular heparin-like molecules are reduced by inflammation, which interferes with the natural anticoagulant pathways (49) .

The second potential mechanism is virus-induced endothelial dysfunction.

SARS-CoV-2 is capable of directly infecting the vascular endothelium by entering cells via angiotensin-converting enzyme receptors (50) , which results in the massive release of plasminogen activators and inhibition of fibrinolysis (51) . In SARS-CoV-1-infected patients, high plasma tissue-type plasminogen activator (t-PA) concentrations are observed (52) . The third putative mechanism is complement activation in viral pneumonia (53) . Deposits of terminal complement components have been observed in the lungs of COVID-19 patients, indicating that dysregulated complement activation contributes to coagulopathy in COVID-19 patients (54) . Other clinical factors, such as hypoxemia, hyperthermia, and hypovolemia, may also enhance the hypercoagulable state in COVID-19 (55) .

Unfortunately, our findings suggest that anticoagulation is unlikely to protect against COVID-19-related mortality. A previous meta-analysis (56) These factors may have introduced heterogeneity, which could affect the results.

In summary, we reported a high pooled incidence of VTE and the need for coagulation monitoring in patients diagnosed with COVID-19. Additional high-quality data are needed to understand the risk of VTE, and the effects of anticoagulation on prognosis and mortality, in COVID-19 patients.

This study was supported by Natural Science Foundation of Zhejiang Province (Grant No. LY20H090012).

The authors declare no conflict of interest.

No ethical approval was required for this review as all data were already published in peer-reviewed journals. No patients were involved in the design, conduct or interpretation of our review. 

The impact of 2019 novel coronavirus on heart injury: A Systematic review and Meta-analysis

Management of acute kidney injury in patients with COVID-19

Manifestations and prognosis of gastrointestinal and liver involvement in patients with COVID-19: a systematic review and meta-analysis

Coagulopathy of Coronavirus Disease

COVID-19 and acute coagulopathy in pregnancy

A Case of Coronavirus Disease 2019 With Concomitant Acute Cerebral Infarction and Deep Vein Thrombosis

Acute Thrombosis of an Aortic Prosthetic Graft in a Patient with Severe COVID-19-Related Pneumonia

Autopsy Findings and Venous Thromboembolism in Patients With COVID-19

COVID and Coagulation: Bleeding and Thrombotic Manifestations of SARS-CoV2 Infection

Systematic assessment of venous thromboembolism in COVID-19 patients receiving thromboprophylaxis: incidence and role of D-dimer as predictive factors

Pulmonary embolism in patients with Covid-19 pneumonia

Prevalence of venous thromboembolism in patients with severe novel coronavirus pneumonia

Incidence of asymptomatic deep vein thrombosis in patients with COVID-19 pneumonia and elevated D-dimer levels

Image-proven thromboembolism in patients with severe COVID-19 in a tertiary critical care unit in the United Kingdom

High risk of thrombosis in patients with severe SARS-CoV-2 infection: a multicenter prospective cohort study

Confirmation of the high cumulative incidence of thrombotic complications in critically ill ICU patients with COVID-19: An updated analysis

Acute Pulmonary Embolism in COVID-19 Patients on CT Angiography and Relationship to D-Dimer Levels

High incidence of venous thromboembolic events in anticoagulated severe COVID-19 patients

Venous and arterial thromboembolic complications in COVID-19 patients admitted to an academic hospital in

Incidence of venous thromboembolism in hospitalized patients with COVID-19

Impact of anticoagulation prior to COVID-19 infection: a propensity score-matched cohort study

Cochrane handbook for systematic reviews of interventions version 5.1.0. The Cochrane collaboration. Available at: www.cochrane-handbook.org

Quantitative methods in the review of epidemiologic literature

Quantifying heterogeneity in a meta-analysis

Measuring inconsistency in meta-analyses

Hematological findings and complications of COVID-19

Attention should be paid to venous thromboembolism prophylaxis in the management of COVID-19

Profiling serum cytokines in COVID-19 patients reveals IL-6 and IL-10 are disease severity predictors

The Role of Cytokines including Interleukin-6 in COVID-19 induced Pneumonia and Macrophage Activation Syndrome-Like Disease

Relationships among lymphocyte subsets, cytokines, and the pulmonary inflammation index in coronavirus (COVID-19) infected patients

High IL-6/IFN-gamma ratio could be associated with severe disease in COVID-19 patients

Activation of coagulation by administration of recombinant factor VIIa elicits interleukin 6 (IL-6) and IL-8 release in healthy human subjects

Ambient particulate matter accelerates coagulation via an IL-6-dependent pathway

Safety and efficacy of paediatric outpatient radiofrequency catheter ablations

Pulmonary Vascular Endothelialitis, Thrombosis, and Angiogenesis in Covid-19

Acute fibrinolysis shutdown occurs early in septic shock and is associated with increased morbidity and mortality: results of an observational pilot study

Immunothrombosis in Acute Respiratory Distress Syndrome: Cross Talks between Inflammation and Coagulation

Coagulation disorders in coronavirus infected patients: COVID-19, SARS-CoV-1, MERS-CoV and lessons from the past

Complement Activation Contributes to Severe Acute Respiratory Syndrome Coronavirus Pathogenesis. mBio

Complement associated microvascular injury and thrombosis in the pathogenesis of severe COVID-19 infection: A report of five cases

Hyperinflammation and derangement of renin-angiotensin-aldosterone system in COVID-19: A novel hypothesis for clinically suspected hypercoagulopathy and microvascular immunothrombosis

Risk factors of critical & mortal COVID-19 cases: A systematic literature review and meta-analysis